{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:07:50Z","timestamp":1788908870617,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Key Laboratory of the Jiangsu Higher Education Institutions for Nucleic Acid & Cell Fate Regulatio","award":["202525"],"award-info":[{"award-number":["202525"]}]},{"name":"The NationalNatural Science Foundation of China","award":["82072909"],"award-info":[{"award-number":["82072909"]}]},{"name":"The Postgraduate Research & Practice Innovation Program of Jiangsu Province","award":["SJCX24_2343"],"award-info":[{"award-number":["SJCX24_2343"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer (BC) is one of the most common malignant tumors in women worldwide, with metastasis and recurrence constituting major therapeutic challenges. F-Box Protein 5(FBXO5), a core component of the E3 ubiquitin ligase complex, is overexpressed in multiple cancers, but its specific role and underlying mechanism in BC remain unclear and require further investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We screened E3 ubiquitin ligase-related cancer dependency genes by integrating data from the DepMap and UniProt databases, and further analyzed transcriptomic data from TCGA and GEO to identify the candidate gene FBXO5. We then validated its expression at the mRNA and protein levels in BC tissues from two independent centers and in cell lines, employing qRT-PCR, Western blot, and immunohistochemistry.The effects of FBXO5 on the proliferation, migration, and invasion abilities of BC cells were evaluated in vitro and in vivo through colony formation, CCK8, Transwell assays, wound healing assays, IHC, and subcutaneous tumor formation in nude mice. The interactions between FBXO5 and proteins, as well as its main functions and pathways, were investigated using Co-IP, mass spectrometry, immunofluorescence confocal microscopy, molecular docking and bioinformatics analysis, with results validated by rescue experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mRNA and protein expression levels of FBXO5 were significantly upregulated in BC tissues from two centers, high expression of FBXO5 was significantly correlated with adverse clinicopathological features, including larger tumor size, positive nodal status, and elevated Ki-67, and was associated with poor overall survival (OS) and disease-free survival (DFS).In vitro and in vivo experiments confirmed that FBXO5 significantly affected the proliferation, invasion, and migration abilities of BC cells. Mechanistically, Co-IP, mass spectrometry, molecular docking and immunofluorescence confocal microscopy experiments confirmed that FBXO5 directly interacts with ribosomal protein L23a (RPL23A) and promotes its polyubiquitination at the K48 chain, thereby regulating its degradation. Further experiments showed that the ubiquitination-mediated degradation of RPL23A led to a decrease in the stability of Tumor Protein p53(p53) and facilitated its degradation by Proto-Oncogene MDM2 (MDM2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study establishes the existence of a novel FBXO5\/RPL23A\/MDM2\/p53 oncogenic axis in BC. These findings thereby nominate FBXO5 as a promising therapeutic target for BC intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-026-02335-3","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T22:44:51Z","timestamp":1782341091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FBXO5 regulates RPL23A to promote MDM2-mediated p53 degradation and facilitate malignant progression of breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Jianwen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longdi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyuan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"3","key":"2335_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"2335_CR2","doi-asserted-by":"publisher","first-page":"1410017","DOI":"10.3389\/fbioe.2024.1410017","volume":"12","author":"L Miao","year":"2024","unstructured":"Miao L, Kang Y, Zhang XF. Nanotechnology for the theranostic opportunity of breast cancer lung metastasis: recent advancements and future challenges. Front Bioeng Biotechnol. 2024;12:1410017. https:\/\/doi.org\/10.3389\/fbioe.2024.1410017. Published 2024 May 31.","journal-title":"Front Bioeng Biotechnol"},{"key":"2335_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13578-019-0314-y","volume":"9","author":"X Tang","year":"2019","unstructured":"Tang X, Huang Y, Lei J, Luo H, Zhu X. The single-cell sequencing: new developments and medical applications. Cell Biosci. 2019;9:53. https:\/\/doi.org\/10.1186\/s13578-019-0314-y. Published 2019 Jun 26.","journal-title":"Cell Biosci"},{"key":"2335_CR4","doi-asserted-by":"publisher","unstructured":"Chen M, Feng M, Lei H, Dan Mo, Ren S, Yang D. The development of the occurrence and metastasis of breast cancer by single-cell sequencing. Cancer Cell Int. 2024;24(1):349. Published 2024 Oct 26. https:\/\/doi.org\/10.1186\/s12935-024-03531-x.","DOI":"10.1186\/s12935-024-03531-x"},{"key":"2335_CR5","doi-asserted-by":"crossref","unstructured":"Mertins P, Mani DR, Ruggles KV et al. Proteogenomics connects somatic mutations to signalling in breast cancer[J]. Nat. 2016;534(7605):55\u201362.","DOI":"10.1038\/nature18003"},{"key":"2335_CR6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.semcancer.2018.04.001","volume":"55","author":"T Zhan","year":"2019","unstructured":"Zhan T, Rindtorff N, Betge J, Ebert MP, Boutros M. CRISPR\/Cas9 for cancer research and therapy. Semin Cancer Biol. 2019;55:106\u201319. https:\/\/doi.org\/10.1016\/j.semcancer.2018.04.001.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2335_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","volume":"21","author":"SW Wang","year":"2022","unstructured":"Wang SW, Gao C, Zheng YM, et al. Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer. Mol Cancer. 2022;21(1):57. https:\/\/doi.org\/10.1186\/s12943-022-01518-8. Published 2022 Feb 21.","journal-title":"Mol Cancer"},{"issue":"7753","key":"2335_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan FM, Iorio F, Picco G, et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature. 2019;568(7753):511\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1103-9.","journal-title":"Nature"},{"issue":"3","key":"2335_CR9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, et al. Defining a Cancer Dependency Map. Cell. 2017;170(3):564\u2013e57616. https:\/\/doi.org\/10.1016\/j.cell.2017.06.010.","journal-title":"Cell"},{"issue":"1","key":"2335_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh R, Shibue T, Dempster JM, Hahn WC, Vazquez F. The present and future of the Cancer Dependency Map. Nat Rev Cancer. 2025;25(1):59\u201373. https:\/\/doi.org\/10.1038\/s41568-024-00763-x.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2335_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.molmed.2023.05.006","volume":"29","author":"D Han","year":"2023","unstructured":"Han D, Wang L, Jiang S, Yang Q. The ubiquitin-proteasome system in breast cancer. Trends Mol Med. 2023;29(8):599\u2013621. https:\/\/doi.org\/10.1016\/j.molmed.2023.05.006.","journal-title":"Trends Mol Med"},{"issue":"10","key":"2335_CR12","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","volume":"21","author":"B Dale","year":"2021","unstructured":"Dale B, Cheng M, Park KS, Kaniskan H\u00dc, Xiong Y, Jin J. Advancing targeted protein degradation for cancer therapy. Nat Rev Cancer. 2021;21(10):638\u201354. https:\/\/doi.org\/10.1038\/s41568-021-00365-x.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2335_CR13","first-page":"1456","volume":"12","author":"J Gao","year":"2022","unstructured":"Gao J, Yang D, Cao R, et al. The role of Fbxo5 in the development of human malignant tumors. Am J Cancer Res. 2022;12(4):1456\u201364. Published 2022 Apr 15.","journal-title":"Am J Cancer Res"},{"issue":"20","key":"2335_CR14","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/S0960-9822(00)80020-2","volume":"9","author":"C Cenciarelli","year":"1999","unstructured":"Cenciarelli C, Chiaur DS, Guardavaccaro D, Parks W, Vidal M, Pagano M. Identification of a family of human F-box proteins. Curr Biol. 1999;9(20):1177\u20139. https:\/\/doi.org\/10.1016\/S0960-9822(00)80020-2.","journal-title":"Curr Biol"},{"issue":"5","key":"2335_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/ncb785","volume":"4","author":"JY Hsu","year":"2002","unstructured":"Hsu JY, Reimann JD, S\u00f8rensen CS, Lukas J, Jackson PK. E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1). Nat Cell Biol. 2002;4(5):358\u201366. https:\/\/doi.org\/10.1038\/ncb785.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"2335_CR16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/s0092-8674(01)00361-0","volume":"105","author":"JD Reimann","year":"2001","unstructured":"Reimann JD, Freed E, Hsu JY, Kramer ER, Peters JM, Jackson PK. Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex. Cell. 2001;105(5):645\u201355. https:\/\/doi.org\/10.1016\/s0092-8674(01)00361-0.","journal-title":"Cell"},{"issue":"3","key":"2335_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.humpath.2012.03.030","volume":"44","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Tang Q, Ni R, et al. Early mitotic inhibitor-1, an anaphase-promoting complex\/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1). Hum Pathol. 2013;44(3):365\u201373. https:\/\/doi.org\/10.1016\/j.humpath.2012.03.030.","journal-title":"Hum Pathol"},{"issue":"8","key":"2335_CR18","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00432-018-2653-1","volume":"144","author":"K Wang","year":"2018","unstructured":"Wang K, Qu X, Liu S, et al. Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma. J Cancer Res Clin Oncol. 2018;144(8):1509\u201321. https:\/\/doi.org\/10.1007\/s00432-018-2653-1.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2335_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/PGP.0b013e31825554e9","volume":"32","author":"KW Min","year":"2013","unstructured":"Min KW, Park MH, Hong SR, et al. Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3. Int J Gynecol Pathol. 2013;32(1):3\u201314. https:\/\/doi.org\/10.1097\/PGP.0b013e31825554e9.","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"2335_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3892\/ol.2016.4611","volume":"12","author":"C Guan","year":"2016","unstructured":"Guan C, Zhang J, Zhang J, Shi H, Ni R. Enhanced expression of early mitotic inhibitor-1 predicts a poor prognosis in esophageal squamous cell carcinoma patients. Oncol Lett. 2016;12(1):114\u201320. https:\/\/doi.org\/10.3892\/ol.2016.4611.","journal-title":"Oncol Lett"},{"key":"2335_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3389\/fonc.2018.00374","volume":"8","author":"J Tang","year":"2018","unstructured":"Tang J, Kong D, Cui Q, et al. Prognostic Genes of Breast Cancer Identified by Gene Co-expression Network Analysis. Front Oncol. 2018;8:374. https:\/\/doi.org\/10.3389\/fonc.2018.00374. Published 2018 Sep 11.","journal-title":"Front Oncol"},{"issue":"12","key":"2335_CR22","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers RM, Bryan JG, McFarland JM, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49(12):1779\u201384. https:\/\/doi.org\/10.1038\/ng.3984.","journal-title":"Nat Genet"},{"key":"2335_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semcancer.2024.05.001","volume":"101","author":"Y Huang","year":"2024","unstructured":"Huang Y, Che X, Wang PW, Qu X. p53\/MDM2 signaling pathway in aging, senescence and tumorigenesis. Semin Cancer Biol. 2024;101:44\u201357. https:\/\/doi.org\/10.1016\/j.semcancer.2024.05.001.","journal-title":"Semin Cancer Biol"},{"issue":"26","key":"2335_CR24","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1182\/blood.2023020731","volume":"143","author":"T Brummer","year":"2024","unstructured":"Brummer T, Zeiser R. The role of the MDM2\/p53 axis in antitumor immune responses. Blood. 2024;143(26):2701\u20139. https:\/\/doi.org\/10.1182\/blood.2023020731.","journal-title":"Blood"},{"issue":"14","key":"2335_CR25","first-page":"1001","volume":"1","author":"UM Moll","year":"2003","unstructured":"Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res. 2003;1(14):1001\u20138.","journal-title":"Mol Cancer Res"},{"issue":"4","key":"2335_CR26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.18632\/oncotarget.1784","volume":"5","author":"TH Kim","year":"2014","unstructured":"Kim TH, Leslie P. Zhang Ribosomal proteins as unrevealed caretakers for cellular stress and genomic instability. Oncotarget. 2014;5(4):860\u201371.","journal-title":"Oncotarget"},{"issue":"5","key":"2335_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccr.2009.09.024","volume":"16","author":"Y Zhang","year":"2009","unstructured":"Zhang Y. Lu Signaling to p53: ribosomal proteins find their way. Cancer Cell. 2009;16(5):369\u201377.","journal-title":"Cancer Cell"},{"issue":"3","key":"2335_CR28","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/nar\/gkt971","volume":"42","author":"D Bai","year":"2014","unstructured":"Bai D, Zhang J, Xiao W. Zheng Regulation of the HDM2-p53 pathway by ribosomal protein L6 in response to ribosomal stress. Nucleic Acids Res. 2014;42(3):1799\u2013811.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"2335_CR29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/ncb1858","volume":"11","author":"S Fumagalli","year":"2009","unstructured":"Fumagalli S, Di Cara A, Neb-Gulati A, Natt F, Schwemberger S, Hall J, Babcock GF, Bernardi R, Pandolfi PP. Thomas Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol. 2009;11(4):501\u20138.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"2335_CR30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/onc.2015.104","volume":"35","author":"A Bailly","year":"2016","unstructured":"Bailly A, Perrin A, Bou Malhab LJ, Pion E, Larance M, Nagala M, Smith P, O\u2019Donohue MF, Gleizes PE, Zomerdijk J, Lamond AI. Xirodimas The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway. Oncogene. 2016;35(4):415\u201326.","journal-title":"Oncogene"},{"issue":"53","key":"2335_CR31","doi-asserted-by":"publisher","first-page":"90651","DOI":"10.18632\/oncotarget.21544","volume":"8","author":"B Cao","year":"2017","unstructured":"Cao B, Fang Z, Liao P, Zhou X, Xiong J, Zeng S, Lu H. Cancer-mutated ribosome protein L22 (RPL22\/eL22) suppresses cancer cell survival by blocking p53-MDM2 circuit. Oncotarget. 2017;8(53):90651\u201361.","journal-title":"Oncotarget"},{"issue":"3","key":"2335_CR32","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/onc.2012.63","volume":"32","author":"X Zhou","year":"2013","unstructured":"Zhou X, Hao Q, Liao J, Zhang Q, Lu H. Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene. 2013;32(3):388\u201396.","journal-title":"Oncogene"},{"issue":"13","key":"2335_CR33","doi-asserted-by":"publisher","first-page":"16217","DOI":"10.18632\/oncotarget.7479","volume":"7","author":"X He","year":"2016","unstructured":"He X, Li Y, Dai MS. Sun Ribosomal protein L4 is a novel regulator of the MDM2-p53 loop. Oncotarget. 2016;7(13):16217\u201326.","journal-title":"Oncotarget"},{"issue":"1","key":"2335_CR34","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1186\/s12967-025-06592-2","volume":"23","author":"J Zhao","year":"2025","unstructured":"Zhao J, Li Y, Zhu J, Li H, Jin X. Ubiquitination in hepatocellular carcinoma immunity. J Transl Med. 2025;23(1):574. https:\/\/doi.org\/10.1186\/s12967-025-06592-2. Published 2025 May 23.","journal-title":"J Transl Med"},{"key":"2335_CR35","doi-asserted-by":"publisher","first-page":"1220108","DOI":"10.3389\/fendo.2023.1220108","volume":"14","author":"Z Ye","year":"2023","unstructured":"Ye Z, Yang J, Jiang H, Zhan X. The roles of protein ubiquitination in tumorigenesis and targeted drug discovery in lung cancer. Front Endocrinol (Lausanne). 2023;14:1220108. https:\/\/doi.org\/10.3389\/fendo.2023.1220108. Published 2023 Sep 19.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2335_CR36","doi-asserted-by":"publisher","unstructured":"Guo H, Wei J, Zhang Y et al. Protein ubiquitination in ovarian cancer immunotherapy: The progress and therapeutic strategy. Genes Dis. 2023;11(6):101158. Published 2023 Oct 29. https:\/\/doi.org\/10.1016\/j.gendis.2023.101158.","DOI":"10.1016\/j.gendis.2023.101158"},{"issue":"1","key":"2335_CR37","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12943-024-02046-3","volume":"23","author":"F Liu","year":"2024","unstructured":"Liu F, Chen J, Li K, et al. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches. Mol Cancer. 2024;23(1):148. https:\/\/doi.org\/10.1186\/s12943-024-02046-3. Published 2024 Jul 25.","journal-title":"Mol Cancer"},{"issue":"4","key":"2335_CR38","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrc3700","volume":"14","author":"Z Wang","year":"2014","unstructured":"Wang Z, Liu P, Inuzuka H, Wei W. Roles of F-box proteins in cancer. Nat Rev Cancer. 2014;14(4):233\u201347. https:\/\/doi.org\/10.1038\/nrc3700.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2335_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41419-024-06421-2","volume":"15","author":"J Ji","year":"2024","unstructured":"Ji J, Jing A, Ding Y, et al. FBXO5-mediated RNF183 degradation prevents endoplasmic reticulum stress-induced apoptosis and promotes colon cancer progression. Cell Death Dis. 2024;15(1):33. https:\/\/doi.org\/10.1038\/s41419-024-06421-2. Published 2024 Jan 11.","journal-title":"Cell Death Dis"},{"issue":"2","key":"2335_CR40","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.molcel.2018.11.003","volume":"73","author":"A Marzio","year":"2019","unstructured":"Marzio A, Puccini J, Kwon Y, et al. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers. Mol Cell. 2019;73(2):224\u2013e2376. https:\/\/doi.org\/10.1016\/j.molcel.2018.11.003.","journal-title":"Mol Cell"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02335-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02335-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02335-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:44:02Z","timestamp":1788907442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02335-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2335"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02335-3","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The human-related component of this study was reviewed and approved by the Ethics Committees of Northern Jiangsu People\u2019s Hospital and Xinghua People\u2019s Hospital, and was conducted in accordance with the Declaration of Helsinki. The animal-related component was reviewed and approved by the Animal Welfare and Ethics Committee of Yangzhou University. All human participants were informed of the study\u2019s purpose and provided written informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have agreed to publish this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"152"}}